vimarsana.com

Latest Breaking News On - Apellis pharmaceuticals price performance - Page 8 : vimarsana.com

Apellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $70 00 at Robert W Baird

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective decreased by Robert W. Baird from $115.00 to $70.00 in a research note published on Tuesday morning, MarketBeat.com reports. Robert W. Baird currently has an outperform rating on the stock. Several other research analysts have also issued reports on APLS. The Goldman Sachs Group lifted […]

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Increased to $115 00 by Analysts at Robert W Baird

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target lifted by Robert W. Baird from $105.00 to $115.00 in a research note published on Monday, FlyOnTheWall reports. Other research analysts have also recently issued research reports about the company. HC Wainwright increased their target price on Apellis Pharmaceuticals from $87.00 to $100.00 in a […]

Research Analysts Offer Predictions for Apellis Pharmaceuticals, Inc s Q2 2025 Earnings (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Investment analysts at Zacks Research raised their Q2 2025 earnings estimates for Apellis Pharmaceuticals in a note issued to investors on Thursday, July 13th. Zacks Research analyst A. Chakraborty now forecasts that the company will post earnings of $0.41 per share for the quarter, up from their […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.